Last week’s CMD was a clear reminder, in our view, of how hVIVO’s platform breadth has positioned the business for resilient growth into expanding customer demand. While headwinds in human challenge trials (HCTs) characterised the company’s FY25 performance, we believe the business exhibits strong underlying resilience. We reiterate our investment thesis and believe today’s sub-9p level offers an excellent entry point for investors, with our Buy recommendation underpinned by our existing multipl ....
